{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:49:19Z","timestamp":1781196559894,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017632","name":"Henan Provincial Key Laboratory of Medical Polymer Materials Technology and Application, Tuoren Medical Device Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.phrs.2024.107340","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:29:32Z","timestamp":1722886172000},"page":"107340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab"],"prefix":"10.1016","volume":"207","author":[{"given":"Yanyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beijian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binge","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.phrs.2024.107340_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.phrs.2024.107340_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series","volume":"72","author":"Ference","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2024.107340_bib3","doi-asserted-by":"crossref","unstructured":"Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988, 148(1):36-69.","DOI":"10.1001\/archinte.148.1.36"},{"issue":"25 Suppl 2","key":"10.1016\/j.phrs.2024.107340_bib4","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"23 Suppl 1","key":"10.1016\/j.phrs.2024.107340_bib5","first-page":"Iii39","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2024.107340_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res"},{"issue":"7","key":"10.1016\/j.phrs.2024.107340_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073418","article-title":"Molecular biological and clinical understanding of the statin residual cardiovascular disease risk and peroxisome proliferator-activated receptor alpha agonists and ezetimibe for its treatment","volume":"23","author":"Yanai","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10384","key":"10.1016\/j.phrs.2024.107340_bib8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet (Lond., Engl. )"},{"issue":"1","key":"10.1016\/j.phrs.2024.107340_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2024.107340_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2024.107340_bib11","article-title":"Efficacy and safety of proprotein convertase subtilisin\/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharm."},{"issue":"22","key":"10.1016\/j.phrs.2024.107340_bib12","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"18","key":"10.1016\/j.phrs.2024.107340_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.phrs.2024.107340_bib14","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.phrs.2024.107340_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2024.107340_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2024.107340_bib17","first-page":"115","article-title":"ESC\/EAS Guidelines for the Management of Dyslipidaemias.","volume":"70","author":"Catapano","year":"2016","journal-title":"Rev. Esp. Cardiol. (Engl. Ed. ) 2017"},{"issue":"9753","key":"10.1016\/j.phrs.2024.107340_bib18","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2024.107340_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","article-title":"Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS)","volume":"235","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.phrs.2024.107340_bib20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study II","volume":"44","author":"Gong","year":"2021","journal-title":"Clin. Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107340_bib21","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins\u3000- ODYSSEY JAPAN randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ. J."},{"issue":"1","key":"10.1016\/j.phrs.2024.107340_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107340_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","article-title":"Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"3","author":"Qi","year":"2023","journal-title":"JACC Asia"},{"issue":"4","key":"10.1016\/j.phrs.2024.107340_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","article-title":"The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Imbalzano","year":"2023","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"issue":"8","key":"10.1016\/j.phrs.2024.107340_bib25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","article-title":"Proprotein convertase subtilisin\/kexin type 9 in kidney disease","volume":"34","author":"Schmit","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"issue":"4","key":"10.1016\/j.phrs.2024.107340_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.tcm.2014.10.015","article-title":"2013 ACC\/AHA cholesterol treatment guideline: paradigm shifts in managing atherosclerotic cardiovascular disease risk","volume":"25","author":"Finkel","year":"2015","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.phrs.2024.107340_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.phrs.2024.107340_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-Lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.phrs.2024.107340_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107340_bib30","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2024.107340_bib31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"issue":"9965","key":"10.1016\/j.phrs.2024.107340_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.phrs.2024.107340_bib33","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.xphs.2018.07.016","article-title":"Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants?","volume":"107","author":"Singh","year":"2018","journal-title":"J. Pharm. Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824002858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824002858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T21:00:40Z","timestamp":1725051640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824002858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"alternative-id":["S1043661824002858"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107340","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107340"}}